Lung Cancer
Conference Coverage
SCLC: Bispecific antibody shows phase 1 promise
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
From the Journals
Warning on use of sotorasib after ICI in lung cancer
“We suggest avoiding starting sotorasib within 30 days from the last anti–PD-(L)1 infusion.”
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Feature
The breathtaking effects of climate change
“What we’re going to see is not just new diseases but also exacerbation of chronic diseases.”
Latest News
Asthma tied to increased risk for multiple cancers
Treatment with an inhaled steroid may lower that risk, perhaps by keeping inflammation in check.
From the Journals
Plasma monitoring supports earlier osimertinib treatment in lung cancer patients
More patients met progression-free survival endpoints after shorter stint on gefitinib.
From the Journals
New clues to how air pollution fuels lung cancer in nonsmokers
Although smoking remains the chief risk factor for lung cancer, outdoor air pollution causes roughly 1 in 10 cases.
From the Journals
Cancer pain declines with cannabis use
Lower use of other meds was also seen in patients who used cannabis.
From the Journals
First guideline for treating oligometastatic NSCLC
An increasing number of radiation oncologists and multidisciplinary teams are now using local therapy beyond palliative care for these patients....
Conference Coverage
Durvalumab pre, post surgery in NSCLC: Practice changing?
A new study’s findings confirm the benefits of neoadjuvant immunotherapy.